Elshenawy, M., Badran, A., Elshentenawy, A., Eldali, A., Memon, M. (2019). Outcome of Treatment of Giant-Cell Tumor of Bone: A Single-Institutional Retrospective Study. Research in Oncology, 15(1), 9-14. doi: 10.21608/resoncol.2019.7254.1072
Mahmoud A. Elshenawy; Ahmed Badran; Ayman Elshentenawy; Abdelmonem Eldali; Muhammad Memon. "Outcome of Treatment of Giant-Cell Tumor of Bone: A Single-Institutional Retrospective Study". Research in Oncology, 15, 1, 2019, 9-14. doi: 10.21608/resoncol.2019.7254.1072
Elshenawy, M., Badran, A., Elshentenawy, A., Eldali, A., Memon, M. (2019). 'Outcome of Treatment of Giant-Cell Tumor of Bone: A Single-Institutional Retrospective Study', Research in Oncology, 15(1), pp. 9-14. doi: 10.21608/resoncol.2019.7254.1072
Elshenawy, M., Badran, A., Elshentenawy, A., Eldali, A., Memon, M. Outcome of Treatment of Giant-Cell Tumor of Bone: A Single-Institutional Retrospective Study. Research in Oncology, 2019; 15(1): 9-14. doi: 10.21608/resoncol.2019.7254.1072
Outcome of Treatment of Giant-Cell Tumor of Bone: A Single-Institutional Retrospective Study
1Medical Oncology Section, Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
2Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Menoufia University, Shebin El Kom, Egypt
3Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
4Kasr El-Aini Centre of Clinical Oncology and Nuclear Medicine (NEMROCK), Faculty of Medicine, Cairo University, Cairo, Egypt
5Department of Biostatistics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Abstract
Background: Giant-cell tumor of bone (GCTB) is a locally aggressive tumor which metastasizes infrequently to the lungs. The standard treatment of GCTB was surgery until the approval of denosumab. Aim: To describe the outcome of treatment of this rare tumor and to determine factors that influence survival. Methods: Retrospective review of the medical records of GCTB patients treated at our institution. Collected data includes: clinicopathological data, treatment modalities and possible prognostic factors. Results: Forty-two patients were identified between May 2008 and November 2017. Their median age was 31 years, and the majority (62%) were females. The commonest primary sites were the upper and lower limbs (50% and 43%, respectively). Eight (19%) patients initially presented with lung metastases. Thirteen (31%) patients received denosumab as first line treatment before surgery and 12 of them underwent surgery post-denosumab. Denosumab was given after recurrence in 12 (29%) patients [8 (19%) with lung metastasis and 4 (10%) with localized disease]. The objective response rate to denosumab after recurrence was 50%. Four (10%) patients achieved complete response and 2 (5%) partial response. After a median follow up of 4.7 years, 6 (14%) patients had local recurrence and 8 (19%) had lung metastasis with no recorded deaths. The 5-year progression-free survival rate was 61%. Conclusion: Denosumab is effective and tolerable in the management of GCTB preoperatively in localized disease to facilitate surgery and in the management of metastatic disease. Multi-institutional prospective studies are needed for further assessment.
View on SCiNiTO
Top